- Home
- MRNA vs EXPD Comparison
MRNA vs EXPD Comparison
Compare MRNA & EXPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | EXPD |
|---|---|---|
| Founded | 2010 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 19.6B |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MRNA | EXPD |
|---|---|---|
| Price | $45.54 | $148.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 11 |
| Target Price | $34.27 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 5.1M | 877.9K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.04% |
| EPS Growth | ★ 21.77 | 4.02 |
| EPS | N/A | ★ 5.95 |
| Revenue | ★ $19,263,000,000.00 | $6,920,948,000.00 |
| Revenue This Year | $9.36 | $2.71 |
| Revenue Next Year | $15.43 | $3.74 |
| P/E Ratio | ★ N/A | $24.81 |
| Revenue Growth | 4.29 | ★ 13.49 |
| 52 Week Low | $22.28 | $106.00 |
| 52 Week High | $59.55 | $167.19 |
Technical Indicators
Market Signals| Indicator | MRNA | EXPD |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 54.98 |
| Support Level | $23.52 | $140.40 |
| Resistance Level | $55.36 | $151.92 |
| Average True Range (ATR) | 2.76 | 2.85 |
| MACD | -0.87 | 0.28 |
| Stochastic Oscillator | 7.99 | 65.62 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About EXPD Expeditors International of Washington Inc.
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.